Novel Pharmaceutical Solvent-Water Separation System

新型制药溶剂-水分离系统

• 批准号: 7326107
• 负责人: Stuart Nemser
• 金额: $ 40.87万
• 依托单位: COMPACT MEMBRANE SYSTEMS, INC.
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-05-01 至 2009-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7326107
• 关键词: Air; Alcohols; Amines; Area; Biological; Biological Models; Biomass; Capital; Chemical Industry; Chemicals; Commit; Compatible; Condition; Data; Dehydration; Drug Industry; Economics; Environment; Esters; Ethanol; Evaluation; Family; Fiber; Flame Retardants; Gasoline; Industry; Isopropanol; Ketones; Lead; Liquid substance; Marketing; Medal; Membrane; Methanol; Names; Nature; Numbers; Oils; Operating System; Operative Surgical Procedures; Organic solvent product; Oxygen; Performance; Permeability; Pharmacologic Substance; Phase; Polytetrafluoroethylene; Polyvinyl Alcohol; Process; Range; Rate; Recovery; Relative (related person); Research Personnel; Resistance; Resources; Route; Savings; Side; Silicon Dioxide; Site; Solvents; Structure; System; Technology; Temperature; Testing; Today; Water; Work; base; chemical reaction; chemical stability; commercialization; concept; cost; cost effective; design; engineering design; improved; innovation; interest; novel; organic acid; polyvinylidene fluoride; programs; vapor

DESCRIPTION (provided by applicant): In Phase I we exceeded all key objectives. We demonstrated in both pervaporation and vapor separation the combination of high membrane permeation and high membrane separation when evaluating isopropyl alcohol (IPA)-Water separation. Membrane stability, which had been concern of reviewers, was shown to be excellent and far superior to other commercial membranes. CMS membranes were shown to be stable up to 130¿C and over the whole compositional operating range. Economic evaluations showed the CMS membranes to have in excess of 80% capital savings compared to existing drying processes. In addition to work on IPA-water, two other pharmaceutical solvents were successfully evaluated. Leaching studies have shown the CMS membranes to be stable. Based on results and commercialization analysis the CMS system is seen as a platform technology. Significant opportunities exist in pharmaceutical solvent recovery enhancing chemical reactions, chemical industry solvent recovery, manufacture of fuel grade ethanol and stabilizing industrial esters. With many opportunities, a large number of industrial and pharmaceutical companies as well as leading researchers have committed to actively participate in this program. This participation will enhance overall chances for commercialization. In Phase II we will first fabricate high flux composite membrane modules. Then we would focus our demonstration on IPA-water systems operating in pervaporation (PV) mode. Focus will be on PV since this is the simplest system for the end user. Once successful basic data on IPA-water in PV is obtained we will expand the evaluation to other pharmaceutical solvents and also evaluating membranes in the vapor separation mode. Additional upgrades will include modeling and system design to enhance overall purification; long term testing plus extended solvent leaching tests; develop enhanced membrane modules using commercial hollow fiber supports; building large skid for field testing and expanding our economic evaluation to show superior performance to alternative drying routes. Throughout this Phase II we will work closely with our industrial partners. This program develops a low cost, simple, process to recover pharmaceutical solvents. This will encourage solvent reuse which is environmentally attractive and cost effective. The process will also keep potential biological contaminants out of the environment.

描述(由申请人提供)：在第一阶段，我们超过了所有关键目标。在评估异丙醇(IPA)-水分离时，我们在渗透汽化和气相分离中都证明了高膜渗透率和高膜分离的组合。膜的稳定性一直受到评论家的关注，被证明是非常好的，远远优于其他商业膜。结果表明，CMS膜在130℃和整个组成操作范围内都是稳定的。经济评估表明，与现有的干燥工艺相比，CMS膜节省了80%以上的资本。除了在IPA-水方面的工作外，还成功地评估了另外两种药物溶剂。浸出研究表明，CMS膜是稳定的。根据结果和商业化分析，CMS系统被视为一种平台技术。在医药溶剂回收促进化学反应、化学工业溶剂回收、生产燃料级乙醇和稳定工业酯方面存在重大机遇。有很多机会，大量的工业和制药公司以及领先的研究人员承诺积极参与这一计划。这一参与将增加商业化的整体机会。在第二阶段，我们将首先制造高通量复合膜组件。然后，我们将重点演示渗透汽化(PV)模式下运行的IPA-水系统。重点将放在光伏上，因为这是对最终用户来说最简单的系统。一旦成功地获得了光伏中IPA-水的基本数据，我们将把评估扩展到其他药物溶剂，并在蒸汽分离模式下评估膜。其他升级将包括用于增强整体净化的建模和系统设计；长期测试以及延长的溶剂浸出测试；使用商业中空纤维支撑物开发增强膜组件；构建用于现场测试的大型防滑板，并扩大我们的经济评估，以显示替代干燥路线的卓越性能。在整个第二阶段，我们将与我们的行业合作伙伴密切合作。该项目开发了一种低成本、简单的回收药物溶剂的工艺。这将鼓励对环境有吸引力且具有成本效益的溶剂再利用。这一过程还将把潜在的生物污染物排除在环境之外。